Inogen (NASDAQ:INGN) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Inogen (NASDAQ:INGN) posted its earnings results on Thursday. The medical technology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01, FiscalAI reports. Inogen had a negative return on equity of 12.89% and a negative net margin of 6.94%.The firm had revenue of $95.08 million for the quarter, compared to analyst estimates of $95.23 million.

Here are the key takeaways from Inogen’s conference call:

• Full-year revenue guidance was reduced to $355 million–$361 million from $366 million–$373 million, reflecting ongoing U.S. direct-channel pressure and the timing of international distributor inventory purchases. Management expects third-quarter revenue to be roughly flat year over year.
• International sales increased 15% year over year to $41.3 million, marking the tenth consecutive quarter of double-digit growth. Inogen cited expansion in Eastern Europe, Latin America, and Canada as longer-term growth drivers, although some distributor purchases may be delayed in the second half.
• Profitability improved, with adjusted EBITDA rising 15% year over year to $2.4 million and adjusted gross margin expanding to 45.6%. The company raised full-year adjusted EBITDA guidance to approximately $4 million, up 48% from 2025.
• New products are gaining traction: Boxy has shipped more than 5,000 units, while Aurora CPAP mask customer accounts more than doubled sequentially. Together, Boxy and Aurora contributed slightly more than 100 basis points of second-quarter growth and are expected to accelerate in the second half.
• U.S. POC unit volume grew at a high-single-digit rate, but U.S. revenue fell 2% and rental revenue declined 12% as HMEs increasingly prescribe portable concentrators at the start of therapy, reducing the traditional rental funnel. Management is reviewing options to improve the rental business while investing in B2B sales execution.

Inogen Stock Performance

Inogen stock traded down $0.44 during midday trading on Friday, hitting $6.05. 599,111 shares of the company’s stock were exchanged, compared to its average volume of 222,691. The firm’s 50 day simple moving average is $6.46 and its 200 day simple moving average is $6.38. Inogen has a 12-month low of $5.34 and a 12-month high of $9.13. The stock has a market cap of $163.83 million, a price-to-earnings ratio of -6.72 and a beta of 1.55.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inogen in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Insider Transactions at Inogen

In other news, EVP Boyer Jennifer M. Yi sold 10,938 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $6.60, for a total transaction of $72,190.80. Following the sale, the executive vice president owned 5,039 shares of the company’s stock, valued at $33,257.40. The trade was a 68.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.50% of the stock is owned by corporate insiders.

Institutional Trading of Inogen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INGN. Alliancebernstein L.P. increased its holdings in shares of Inogen by 3.9% during the 3rd quarter. Alliancebernstein L.P. now owns 51,120 shares of the medical technology company’s stock worth $418,000 after buying an additional 1,900 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Inogen by 14.6% in the 4th quarter. Russell Investments Group Ltd. now owns 19,543 shares of the medical technology company’s stock worth $131,000 after purchasing an additional 2,487 shares during the period. Rhumbline Advisers lifted its stake in shares of Inogen by 7.0% in the 2nd quarter. Rhumbline Advisers now owns 39,059 shares of the medical technology company’s stock valued at $275,000 after purchasing an additional 2,561 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Inogen by 4.9% in the 2nd quarter. American Century Companies Inc. now owns 61,238 shares of the medical technology company’s stock valued at $431,000 after purchasing an additional 2,858 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Inogen by 4.5% during the 4th quarter. Barclays PLC now owns 81,980 shares of the medical technology company’s stock worth $551,000 after purchasing an additional 3,515 shares during the period. Hedge funds and other institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.